Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) have been assigned a consensus rating of “Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have issued a report on the stock in the last year is $9.90.
A number of research firms have commented on ORGO. BTIG Research upped their price objective on shares of Organogenesis from $10.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, January 14th. TheStreet upgraded Organogenesis from a “d” rating to a “c” rating in a report on Wednesday, December 2nd. SVB Leerink upped their target price on Organogenesis from $10.00 to $13.00 and gave the company an “outperform” rating in a report on Wednesday, January 20th. Finally, Credit Suisse Group upped their target price on Organogenesis from $8.00 to $9.00 and gave the company an “outperform” rating in a report on Thursday, January 7th.
ORGO stock opened at $15.09 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.50 and a debt-to-equity ratio of 1.54. Organogenesis has a one year low of $2.47 and a one year high of $17.11. The firm has a market capitalization of $1.63 billion, a PE ratio of -251.50 and a beta of 1.84. The firm has a 50-day moving average of $12.38 and a two-hundred day moving average of $6.72.
Several institutional investors and hedge funds have recently bought and sold shares of ORGO. Emerald Advisers LLC bought a new stake in shares of Organogenesis in the fourth quarter valued at approximately $26,000. CWM LLC lifted its position in Organogenesis by 66.8% in the fourth quarter. CWM LLC now owns 4,000 shares of the company’s stock worth $30,000 after purchasing an additional 1,602 shares during the period. Citigroup Inc. lifted its position in Organogenesis by 329.6% in the fourth quarter. Citigroup Inc. now owns 4,176 shares of the company’s stock worth $31,000 after purchasing an additional 3,204 shares during the period. GSA Capital Partners LLP bought a new position in Organogenesis in the third quarter worth $65,000. Finally, Lazard Asset Management LLC lifted its position in Organogenesis by 754.2% in the fourth quarter. Lazard Asset Management LLC now owns 9,840 shares of the company’s stock worth $74,000 after purchasing an additional 8,688 shares during the period. 4.62% of the stock is owned by institutional investors.
Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.
See Also: Capital Gains Distribution
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.